Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 7,827 matching trials from the live ClinicalTrials.gov search.
Not listed No phase listed Observational Accepts healthy volunteers

Undetected Sleep Apnea in the Postanesthesia Acute Care Unit (PACU)

NCT02166879
Conditions
Sleep Apnea, Obstructive
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Conditions
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Active, not recruiting Not applicable Interventional Results available

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Stroke, Ischemic Stroke
Interventions
Mechanical Thrombectomy
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Stanford, California • Orlando, Florida • Atlanta, Georgia + 6 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
Interventions
ORCA-T
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Leukemia
Interventions
tipifarnib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Rochester, New York
Conditions
Labor, Premature
Interventions
Magnesium, Nifedlipine
Drug
Lead sponsor
MemorialCare
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Long Beach, California
Conditions
Acute Kidney Injury
Interventions
Ischemic preconditionin
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cystic Fibrosis
Interventions
Sit to stand test
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 35 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Conditions
Acute Otitis Media, Pediatric Infectious Disease, Ear Infection
Interventions
High Intensity Intervention, Low Intensity Intervention
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
2 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Graft Versus Host Disease, Acute
Interventions
CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids
Biological · Drug
Lead sponsor
Cynata Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more
Conditions
Acute Respiratory Distress Syndrome
Interventions
Budesonide, Placebo, Nebulizer
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Days to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
anti-thymocyte globulin, asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, melphalan, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisolone, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Dutch Childhood Oncology Group
Other
Eligibility
Up to 1 Year
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Memphis, Tennessee • Houston, Texas + 1 more
Conditions
Acute Asthma
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
16 Years to 75 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Myocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old
Interventions
BioMonitor
Device
Lead sponsor
Biotronik SE & Co. KG
Industry
Eligibility
18 Years to 99 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
St Louis, Missouri • Rochester, New York • Grand Forks, North Dakota + 4 more
Conditions
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Mehrdad Abedi, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180, 4 times above target dose MP-3180, ORFM prototype, Iohexol comparator
Drug · Device · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Otitis Media (AOM)
Interventions
Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 36 Months
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more